- Home
- KTTA vs LIPO Comparison
KTTA vs LIPO Comparison
Compare KTTA & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- LIPO
- Stock Information
- Founded
- KTTA 2020
- LIPO 2005
- Country
- KTTA United States
- LIPO United States
- Employees
- KTTA N/A
- LIPO N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- LIPO Health Care
- Exchange
- KTTA Nasdaq
- LIPO Nasdaq
- Market Cap
- KTTA 2.8M
- LIPO 3.1M
- IPO Year
- KTTA 2021
- LIPO 2022
- Fundamental
- Price
- KTTA $0.89
- LIPO $2.99
- Analyst Decision
- KTTA
- LIPO
- Analyst Count
- KTTA 0
- LIPO 0
- Target Price
- KTTA N/A
- LIPO N/A
- AVG Volume (30 Days)
- KTTA 2.3M
- LIPO 39.2K
- Earning Date
- KTTA 05-15-2025
- LIPO 05-14-2025
- Dividend Yield
- KTTA N/A
- LIPO N/A
- EPS Growth
- KTTA N/A
- LIPO N/A
- EPS
- KTTA N/A
- LIPO N/A
- Revenue
- KTTA N/A
- LIPO $519,866.00
- Revenue This Year
- KTTA N/A
- LIPO N/A
- Revenue Next Year
- KTTA N/A
- LIPO N/A
- P/E Ratio
- KTTA N/A
- LIPO N/A
- Revenue Growth
- KTTA N/A
- LIPO 8.88
- 52 Week Low
- KTTA $0.79
- LIPO $1.97
- 52 Week High
- KTTA $7.50
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- KTTA 38.94
- LIPO 58.50
- Support Level
- KTTA $0.87
- LIPO $2.75
- Resistance Level
- KTTA $0.95
- LIPO $3.17
- Average True Range (ATR)
- KTTA 0.07
- LIPO 0.29
- MACD
- KTTA 0.01
- LIPO 0.02
- Stochastic Oscillator
- KTTA 40.41
- LIPO 81.05
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.